Naturally Splendid Responds to Health Canada’s Information Request Notice

Vancouver, British Columbia – TheNewswire – October 16, 2020 – Naturally Splendid Enterprises Ltd. (“Naturally Splendid”, “NSE” or “the Company”) (FRANKFURT:50N) (TSXV:NSP) (OTC:NSPDF) has responded through their joint venture Plasm Pharmaceutical (“Plasm”) to Health Canada’s Information Request Notice (“IRN”). The questions as posed by Health Canada are considered a formality as Plasm Pharmaceutical, continues to prepare for aContinue reading “Naturally Splendid Responds to Health Canada’s Information Request Notice”

Naturally Splendid Closes Private Placement, Secures Laboratory Facility

— Naturally Splendid Enterprises Ltd. (“Naturally Splendid”) (TSXV:NSP) (OTC:NSPDF) (Frankfurt:50N) is pleased to announce that it has closed its non-brokered private placement financing for a total of 15,887,503 units (the “Units”) at $0.06 per Unit, for total gross proceeds of $1,053,250 (the “Offering”). Due to oversubscribed demand, the private placement financing was increased from 14,166,667 Units to 17,554,167.Continue reading “Naturally Splendid Closes Private Placement, Secures Laboratory Facility”

Naturally Splendid Announces Biologic Definitive Agreement and Private Placement

“We continue to make progress on several fronts including significant steps towards beginning a phase 2 clinical trial for a potential COVID-19 treatment.” Founder & CEO Craig Goodwin Vancouver, British Columbia – The Newswire – September 2, 2020 – Naturally Splendid Enterprises Ltd. (“Naturally Splendid”, “NSE” or “the Company”) (FRANKFURT:50N) (TSXV:NSP) (OTC:NSPDF) is pleased to announceContinue reading “Naturally Splendid Announces Biologic Definitive Agreement and Private Placement”

Naturally Splendid –

The Evolution of a Plant-Based Powerhouse Protein – a necessary staple for human life. The progression of where we get our protein is drastically changing in society – worldwide. For centuries, animal protein was the primary choice for protein, yet times are changing.  Plant-based protein (“PB-protein”) is taking the world by storm.  Growing hundreds ofContinue reading “Naturally Splendid –”

Naturally Splendid Ships 20 Tonnes of Hemp to South Korea

— Naturally Splendid Enterprises Ltd. (“Naturally Splendid”) (TSXV:NSP) (OTC:NSPDF) (Frankfurt:50N) provides the following update in regards to shipments of hulled hemp seed exports to South Korea. Naturally Splendid is pleased to announce the finalization of another purchase order for 20 tonnes of hemp seed destined for South Korea. This new sale represents the third shipment of this sizeContinue reading “Naturally Splendid Ships 20 Tonnes of Hemp to South Korea”

Naturally Splendid Provides 2019 in Review and 2020 Outlook

— Naturally Splendid Enterprises Ltd. (“Naturally Splendid”) (TSXV:NSP) (OTC:NSPDF) (Frankfurt:50N) announces its audited financial results for the year ended December 31, 2019. All amounts are in Canadian dollars and are prepared in accordance with International Financial Reporting Standards. Naturally Splendid recorded a net loss and comprehensive loss for the year of $7,030,070 during the year ended December 31,Continue reading “Naturally Splendid Provides 2019 in Review and 2020 Outlook”

Amended: Naturally Splendid Closes Private Placement

“Prior to COVID-19, the plant-based food category was growing at a rate outpacing traditional food channels and we expect this trend to continue post-pandemic times.” Naturally Splendid Enterprises Ltd. (TSXV:NSP) (OTC:NSPDF) (Frankfurt:50N) is pleased to announce that it has closed its non-brokered private placement financing for a total of 42,857,159 units (the “Units”) at $0.035Continue reading “Amended: Naturally Splendid Closes Private Placement”

Naturally Splendid Announces Inventory Produced for Target Drug, Cavaltinib(TM) for Phase 2 COVID 19 Clinical Trial

Vancouver, British Columbia – TheNewswire – June 1, 2020 – Naturally Splendid Enterprises Ltd. (“Naturally Splendid”, “NSE” or “the Company”) (FRANKFURT:50N) (TSXV:NSP) (OTC:NSPDF) is pleased to provide the following progress update for a Phase 2 clinical trial treatment for COVID 19. The Company is now awaiting notification by Health Canada to proceed to the Phase 2 clinical trial stage,Continue reading “Naturally Splendid Announces Inventory Produced for Target Drug, Cavaltinib(TM) for Phase 2 COVID 19 Clinical Trial”